PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 30, 2026Cold Spring Harbor Perspectives in Medicine1 citations

The Global Epidemiology of Tuberculosis: Burden, Trends, and Determinants

View Full Paper
GWGerhard WalzlDGDelia GolettiAZAlimuddin Zumla

Key Points

  • This research aims to quantify global tuberculosis incidence and identify key determinants affecting its spread and mortality.
  • Analyzed global TB infection rates and death statistics from various regions and demographics.
  • Considered the impact of TB/HIV coinfection and drug resistance on TB mortality.
  • Evaluated trends in TB incidence from 2000 to 2022.
  • In 2024, an estimated 10.7 million people developed TB, with a mortality rate of 1.23 million, including 150,000 deaths related to HIV.
  • TB incidence is 131 cases per 100,000 population, with noticeable regional disparities and significant challenges in drug-resistant TB management.
  • Case detection and mortality rates show signs of recovery post-COVID-19, emphasizing the need for renewed TB control efforts.

Abstract

Tuberculosis (TB) remains the leading cause of death from an infectious disease worldwide despite availability of effective treatment. In 2024, an estimated 10.7 million people developed TB disease, including 5.8 million men, 3.7 million women, and 1.2 million children. An estimated 1.23 million people died of TB, including 150,000 deaths among people living with human immunodeficiency virus (HIV). TB occurs in all regions of the world but is highly concentrated in a number of countries and populations, reflecting persistent social, economic, and health-system inequalities. Approximately one-fifth of the world's population has TB infection. TB burden varies markedly by age, sex, geography, and risk profile. TB/HIV coinfection remains a major driver of TB mortality, particularly in sub-Saharan Africa. Children and adolescents account for a substantial and underrecognized share of the global burden. Drug-resistant TB remains a major threat, driven by ongoing transmission and gaps in access to timely diagnosis and effective treatment. Global TB incidence declined between 2000 and 2019 but stalled during the COVID-19 pandemic. Case detection and mortality have partially recovered since 2022. Currently, 131 cases per 100,000 population and funding cuts highlight the fragility of TB control efforts. Sustained reductions in TB burden and achieving WHO End TB goals will require strong political and funder commitments in early diagnosis, expanded prevention, universal access to effective treatment for all forms of TB, strengthened surveillance, and action on the social and structural determinants that drive transmission and disease.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Walzl et al. (2026) studied this question.

synapsesocial.com/papers/69f2f1471e5f7920c6386f3dhttps://doi.org/10.1101/cshperspect.a041982
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 20212024 · 142 citations
  2. 2Global, regional, and national burden of HIV-negative tuberculosis, 1990–2021: Findings from the Global Burden of Disease 2021 Study2024 · 3 citations
  3. 3C28-01 Global Tuberculosis Trends Over Two Decades: The Uneven Path Toward Elimination2026
  4. 4Decadal trends and regional disparities in tuberculosis burden: a comprehensive analysis of global, African, and Southeast Asian data from the GBD 1990–20212025 · 15 citations
  5. 5Global, regional, and national burden of HIV-negative tuberculosis, 1990–2021: findings from the Global Burden of Disease Study 20212024 · 54 citations